What are you looking for? Write the name, title or any keyword related to what you are looking for and select which content category it belongs to. Search Fulltext search Activities Professionals Research groups News - Any - A Randomized, Double-masked, Multicenter, 3-Arm Phase 2/3 Study to Evaluate the Efficacy and Safety of Intravitreal EYE103 Compared with Intravitreal ranibizumab (0.5mg) in Participants with Diabetic Macular Edema Contact Protocol code: EYE-RES-102 EudraCT code: No aplica Pathology: Malalties de l’ull i dels seus annexos Principal investigator: Garrido Marin, Marta Research group: Oftalmologia Service: Oftalmologia Phase: Fase III Recruiting: Open Status: Iniciat Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Estudio de fase 1 del inhibidor de menina ziftomenib en combinación con quimioterapia en niños con leucemia aguda recidivante o resistente al tratamiento con reordenamientos de los genes KMT2A o NUP98, o con mutación en el gen NPM1 Contact Protocol code: ITCC-101/APAL2020K EudraCT code: No aplica Pathology: Tumors Principal investigator: Murillo Sanjuán , Laura Research group: Càncer i malalties hematològiques infantils Service: Oncohematologia Pediàtrica Phase: Fase I Recruiting: Open Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Estudio clínico de fase 3, aleatorizado, controlado con placebo y doble ciego para evaluar la eficacia y la seguridad de molnupiravir (MK-4482) en adultos no hospitalizados con COVID-19 y alto riesgo de progresión de la enfermedad Contact Protocol code: MK-4482-023 EudraCT code: No aplica Pathology: Certes malalties infeccioses i parasitàries Principal investigator: Len Abad, Oscar Research group: Malalties infeccioses Service: Infeccioses Phase: Phase III Recruiting: Closed Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. A Phase 2a, Open-label, Multicenter, Platform Trial to Assessthe Safety, Tolerability, and Efficacy of Inebilizumab andBlinatumomab in Subjects With Select Autoimmune Diseases Contact Protocol code: 20240033 EudraCT code: No aplica Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més Principal investigator: Bestard Matamoros, Oriol Research group: Nefrologia i trasplantament renal Service: Nefrologia Phase: Fase II Recruiting: Closed Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Professionals Ana Lucea Peña Year 2025 Títol Complet Institutional framework agreement for technical and support services in developement of competitive proposals (excluding ERC proposals) (Lot 1) and development of competitive proposals (ERC proposals) (Lot 2) and support services in the post-award management of competitive projects (Lot 3) of the Fundació Hospital Universitari Vall Hebron - Institut de Recerca (VHIR) Expedient FRAMEWORK AGREEMENT FOR TECHNICAL AND SUPPORT SERV Codi 24979135 Data publicació Fri, 7 Feb 2025 - 12:00 Documentos (enllaços) TENDER NOTICE SPECIFIC ADMINISTRATIVE BIDDING CONDITIONS APPENDIX 1.1 PCAP APPENDIX 1.2 PCAP APPENDIX 1.3 PCAP DOCUMENT OF TECHNICAL SPECIFICATIONS MAIN POINTS ON THE DIGITAL TOOL DEUC DEUC XML. INSTRUCTIONS FOR FILLING DEUC AGREEMENT ON THE NEED SUFFICIENCY OF CREDIT CERTIFICATE RESOLUTION ON THE APPOINTMENT OF THE CONTRACT AWARDING COMMITTEE RESOLUTION FOR THE APPROVAL OF THE TENDER RESOLUTION TO MDODIFY ENVELOPE NUM. 3 Year 2025 Títol Complet Contractació del servei d'assegurances de salut privada, a través del pla de compensació flexible, destinat a tot el personal de la Fundació Hospital Universitari Vall Hebron - Institut de Recerca (VHIR) Expedient ASSEGURANCES DE SALUT (PCF) Codi 24979060 Data publicació Thu, 6 Feb 2025 - 12:00 Documentos (enllaços) ANUNCI DE LICITACIÓ PLEC DE CLÀUSULES ADMINISTRATIVES PARTICULARS ANNEX 1 PCAP (word) PLEC DE PRESCRIPCIONS TÈCNIQUES PRINCIPALS PUNTS SOBRE DIGITAL DEUC DEUC FORMAT XML INSTRUCCIONS PER EMPLENAR EL DEUC INFORME DE NECESSITAT CERTIFICAT D'EXISTÈNCIA DE CRÈDIT RESOLUCIÓ DESIGNACIÓ DE LA MESA DE CONTRACTACIÓ RESOLUCIÓ D'APROVACIÓ DE L'EXPEDIENT RESOLUCIÓ DESERT Professionals Emilie Anderssen Nordahl Professionals Anika Pupak I am a Local Research Coordinator at Barcelona site (Vall d’Hebron) of the European Spine Study Group, which I joined in 2023. Professionals Rucsanda Pinteac Professionals Juan Ignacio Rodriguez Gómez Professionals Alba Maria Jiménez Masip Professionals Juan Fernando Fuentes Cabrera I'm a doctor specializing in Otorhinolaryngology and Head and Neck Surgery. Within the ENT department , I work in the head and neck section, with special interest in head and neck cancer and minimally invasive techniques such as robotic surgery, as well as benign pathology in this area. I have a A phase 2, randomized, placebo-controlled, double-blind multiple ascending dose study in patients with cystic fibrosis carrying the 3849 +10 kb C->t mutation to evaluate the safety, tolerability, phamacokinetics and preliminary efficacy of SLP84 Contact Protocol code: SPL84-002 EudraCT code: No aplica Pathology: Malalties del sistema respiratori Principal investigator: Álvarez Fernandez, Antonio Research group: Pneumologia Service: Pneumologia Phase: Phase II Recruiting: Open Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Estudio fase IIb, aleatorizado, doble ciego, controlado con placeboy con comparador activo abierto para evaluar la eficacia, seguridad y tolerabilidad deAZD5004 en adultos con diabetes mellitus tipo 2 Contact Protocol code: D7261C00001 EudraCT code: No aplica Pathology: Malalties endocrines, nutricionals i metabòliques Principal investigator: Ciudin Mihai, Andreea Research group: Diabetis i metabolisme Service: Endocrinologia Phase: Phase II Recruiting: Open Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. “Efficacy and safety of co administered cagrilintide and semaglutide(CagriSema) once weekly versus placebo in participants with type 2diabetes and painful diabetic peripheral neuropathy Contact Protocol code: NN9388-7864 EudraCT code: No aplica Pathology: Symptoms, signs, and abnormal clinical and laboratory findings, not elsewhere classified Principal investigator: Ortiz Zuñiga, Angel Michael Research group: Diabetes and Metabolism Service: Endocrinology Phase: Phase II Recruiting: Open Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Estudio de fase 3, aleatorizado, doble ciego y controlado con tratamiento activo para evaluar el cambio a una pauta semanal de islatravir/lenacapavir por vía oral en personas con VIH-1 con supresión virológica bajo tratamiento con bictegravir/emtricitabina/tenofovir (B/F/TAF) Contact Protocol code: GS-US-563-5925 EudraCT code: No aplica Pathology: Certain infectious and parasitic diseases Principal investigator: Curran Fàbregas, Adria Research group: Infectious Diseases Service: Infectious Phase: Phase III Recruiting: Open Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. ' Efficacy and safety of co-administered cagrilintide and semaglutide(CagriSema 2.4 mg/2.4 mg) once-weekly versus semaglutide 2.4 mg,cagrilintide 2.4 mg and placebo in people with chronic kidneydisease and type 2 diabetes living with overweight or obesity.' Contact Protocol code: NN9388-7700 EudraCT code: No aplica Pathology: Symptoms, signs, and abnormal clinical and laboratory findings, not elsewhere classified Principal investigator: Soler Romeo, Maria Jose Research group: Nephrology and kidney transplantation Service: Nephrology Phase: Phase II Recruiting: Open Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Estudio de fase III, aleatorizado, doble ciego, controlado con placebo y multicéntrico para evaluar la eficacia y la seguridad de anifrolumab en adultos con lupus eritematoso cutáneo subagudo o crónico que son resistentes o intolerantes al tratamiento antipalúdico Contact Protocol code: D346BC00001 EudraCT code: No aplica Pathology: Symptoms, signs, and abnormal clinical and laboratory findings, not elsewhere classified Principal investigator: Cortes Hernandez, Josefina Research group: Reumatologia Service: Reumatologia Phase: Phase II Recruiting: Closed Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician’s choice chemotherapy compared to trastuzumab in combination with physician’s choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on, or are intolerant to, previous trastuzumab deruxtecan treatment. Contact Protocol code: JZP598-303 EudraCT code: No aplica Pathology: Tumors Principal investigator: Escriva de Romaní Muñoz, Santiago Ignacio Service: Oncologia Phase: Phase III Recruiting: Open Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Pagination First page « Previous page ‹ … Page 1396 Page 1397 Current page 1398 Page 1399 Page 1400 … Next page › Last page »
Year 2025 Títol Complet Institutional framework agreement for technical and support services in developement of competitive proposals (excluding ERC proposals) (Lot 1) and development of competitive proposals (ERC proposals) (Lot 2) and support services in the post-award management of competitive projects (Lot 3) of the Fundació Hospital Universitari Vall Hebron - Institut de Recerca (VHIR) Expedient FRAMEWORK AGREEMENT FOR TECHNICAL AND SUPPORT SERV Codi 24979135 Data publicació Fri, 7 Feb 2025 - 12:00 Documentos (enllaços) TENDER NOTICE SPECIFIC ADMINISTRATIVE BIDDING CONDITIONS APPENDIX 1.1 PCAP APPENDIX 1.2 PCAP APPENDIX 1.3 PCAP DOCUMENT OF TECHNICAL SPECIFICATIONS MAIN POINTS ON THE DIGITAL TOOL DEUC DEUC XML. INSTRUCTIONS FOR FILLING DEUC AGREEMENT ON THE NEED SUFFICIENCY OF CREDIT CERTIFICATE RESOLUTION ON THE APPOINTMENT OF THE CONTRACT AWARDING COMMITTEE RESOLUTION FOR THE APPROVAL OF THE TENDER RESOLUTION TO MDODIFY ENVELOPE NUM. 3
Year 2025 Títol Complet Contractació del servei d'assegurances de salut privada, a través del pla de compensació flexible, destinat a tot el personal de la Fundació Hospital Universitari Vall Hebron - Institut de Recerca (VHIR) Expedient ASSEGURANCES DE SALUT (PCF) Codi 24979060 Data publicació Thu, 6 Feb 2025 - 12:00 Documentos (enllaços) ANUNCI DE LICITACIÓ PLEC DE CLÀUSULES ADMINISTRATIVES PARTICULARS ANNEX 1 PCAP (word) PLEC DE PRESCRIPCIONS TÈCNIQUES PRINCIPALS PUNTS SOBRE DIGITAL DEUC DEUC FORMAT XML INSTRUCCIONS PER EMPLENAR EL DEUC INFORME DE NECESSITAT CERTIFICAT D'EXISTÈNCIA DE CRÈDIT RESOLUCIÓ DESIGNACIÓ DE LA MESA DE CONTRACTACIÓ RESOLUCIÓ D'APROVACIÓ DE L'EXPEDIENT RESOLUCIÓ DESERT
